Toxicogenomics discrimination of potential hepatocarcinogenicity of non-genotoxic compounds in rat liver

Journal of Applied Toxicology

Volumn 33, Issue 11, 2013, Pages 1284-1293

  Yamada, Fumihiro ^a   Sumida, Kayo ^a   Uehara, Takeki ^b   Morikawa, Yuji ^c   Yamada, Hiroshi ^c   Urushidani, Tetsuro ^c,d   Ohno, Yasuo ^e  

^a SUMITOMO CHEMICAL CO LTD   (Japan)

^b SHIONOGI AND CO LTD   (Japan)

^c NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

^d DOSHISHA WOMEN'S COLLEGE OF LIBERAL ARTS   (Japan)

^e NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

Author keywords

Gene expression profiles; Hepatocarcinogenicity; Liver; Prediction; Rat; Toxicogenomics

Indexed keywords

ACETYLSALICYLIC ACID; ALCOHOL; ALLYL ALCOHOL; CARBAMAZEPINE; CARBON TETRACHLORIDE; COUMARIN; DIAZEPAM; ETHINYLESTRADIOL; ETHIONAMIDE; ETHIONINE; GRISEOFULVIN; HALOPERIDOL; HEXACHLOROBENZENE; ISONIAZID; KETOCONAZOLE; LABETALOL; METFORMIN; METHAPYRILENE; METHOTREXATE; MEXILETINE; MONOCROTALINE; PARACETAMOL; PHENOBARBITAL; PHENYTOIN; RIFAMPICIN; SALAZOSULFAPYRIDINE; TAMOXIFEN CITRATE; TANNIN; THIOACETAMIDE; TRIAMTERENE; CARCINOGEN; TRANSCRIPTOME;

AMES TEST; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENICITY; CONTROLLED STUDY; GENE EXPRESSION; GENE REGULATORY NETWORK; GENOMICS; IN VIVO STUDY; LIVER CARCINOGENESIS; MALE; MARKER GENE; NONHUMAN; NUCLEOTIDE SEQUENCE; PREDICTION; PRIORITY JOURNAL; RAT; SUPPORT VECTOR MACHINE; TRAINING; VALIDATION PROCESS; ANIMAL; CARCINOGEN TESTING; CHEMICALLY INDUCED; CHEMISTRY; DRUG EFFECTS; EXPERIMENTAL LIVER NEOPLASM; GENE EXPRESSION PROFILING; GENETICS; PREDICTIVE VALUE; SPRAGUE DAWLEY RAT; TOXICOGENETICS;

ANIMALIA; RATTUS;

ANIMALS; CARCINOGENICITY TESTS; CARCINOGENS; GENE EXPRESSION PROFILING; LIVER NEOPLASMS, EXPERIMENTAL; MALE; PREDICTIVE VALUE OF TESTS; RATS, SPRAGUE-DAWLEY; TOXICOGENETICS; TRANSCRIPTOME;

EID: 84884704142     PISSN: 0260437X     EISSN: 10991263     Source Type: Journal    
DOI: 10.1002/jat.2790     Document Type: Article

References (37)

1. Amacher DE, Beck R, Schomake SJ, Kenny CV. 1997. Hepatic microsomal enzyme induction, beta-oxidation, and cell proliferation following administration of clofibrate, gemfibrozil, or bezafibrate in the CD rat. Toxicol. Appl. Pharmacol. 142: 143-150.
2. Belury MA, Moya-Camarena SY, Sun H, Snyder E, Davis JW, Cunningham ML, Vanden Heuvel JP. 1998. Comparison of dose-response relationships for induction of lipid metabolizing and growth regulatory genes by peroxisome proliferators in rat liver. Toxicol. Appl. Pharmacol. 151: 254-261.
3. Boukerche H, Su ZZ, Prévot C, Sarkar D, Fisher PB. 2008. mda-9/Syntenin promotes metastasis in human melanoma cells by activating c-Src. Proc. Natl. Acad. Sci. 105: 15914-15919.
4. Cha MK, Kim IH. 2009. Preferential overexpression of glutaredoxin3 in human colon and lung carcinoma. Cancer Epidemiol. 33: 281-287.
5. Ellinger-Ziegelbauer H, Stuart B, Wahle B, Bomann W, Ahr HJ. 2005. Comparison of the expression profiles induced by genotoxic and nongenotoxic carcinogens in rat liver. Mutat. Res. 575: 61-84.
6. Ellinger-Ziegelbauer H, Gmuender H, Bandenburg A, Ahr HJ. 2008. Prediction of a carcinogenic potential of rat hepatocarcinogens using toxicogenomics analysis of short-term in vivo studies. Mutat. Res. 637: 23-39.
7. Farin K, Schokoroy S, Haklai R, Cohen-Or I, Elad-Sfadia G, Reyes-Reyes ME, Bates PJ, Cox AD, Kloog Y, Pinkas-Kramarski R. 2011. Oncogenic synergism between ErbB1, nucleolin, and mutant Ras. Cancer Res. 71: 2140-2151.
8. Farombi EO, Akinloye O, Akinmoladun CO, Emerole GO. 1999. Hepatic drug metabolizing enzyme induction and serum triacylglycerol elevation in rats treated with chlordiazepoxide, griseofulvin, rifampicin and phenytoin. Clin. Chim. Acta 289: 1-10.
9. Fielden MR, Brennan R, Gollub J. 2007. A gene expression biomarker provides early prediction and mechanistic assessment of hepatic tumor induction by nongenotoxic chemicals. Toxicol. Sci. 99: 90-100.
10. Fujita M, Hayashi I, Yamashina S, Fukamizu A, Itoman M, Majima M. 2005. Angiotensin type 1a receptor signaling-dependent induction of vascular endothelial growth factor in stroma is relevant to tumor-associated angiogenesis and tumor growth. Carcinogenesis 26: 271-279.
11. Hirode M, Ono A, Miyagishima T, Nagao T, Ohno Y, Urushidani T. 2008. Gene expression profiling in rat liver treated with compounds inducing phospholipidosis. Toxicol. Appl. Pharmacol. 229: 290-299.
12. Hirode M, Omura K, Kiyosawa N, Uehara T, Shimuzu T, Ono A, Miyagishima T, Nagao T, Ohno Y, Urushidani T. 2009. Gene expression profiling in rat liver treated with various hepatotoxic-compounds inducing coagulopathy. J. Toxicol. Sci. 34: 281-293.
13. Holden PR, Tugwood JD. 1999. Peroxisome proliferator-activated receptor alpha: role in rodent liver cancer and species differences. J. Mol. Endocrinol. 22: 1-8.
14. James NH, Gill JH, Brindle R, Woodyatt NJ, Macdonald N, Rolfe M, Hasmall SC, Tugwood JD, Holden PR, Roberts RA. 1998. Peroxisome proliferator-activated receptor (PPAR) alpha-regulated growth responses and their importance to hepatocarcinogenesis. Toxicol. Lett. 28: 91-96.
15. Kim MS, Jeong EG, Chung YJ, Yoo NJ, Lee SH. 2008. Absence of somatic mutation of a tumor suppressor gene eukaryotic translation elongation factor 1, epsilon-1 (EEF1E1), in common human cancers. APMIS 116: 832-833.
16. Kirkland D, Aardema M, Henderson L, Müller L. 2005. Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens I. Sensitivity, specificity and relative predictivity. Mutat. Res. 584: 1-256.
17. Kiyosawa N, Ito K, Sakuma K, Niino N, Kanbori M, Yamoto T, Manabe S, Matsunuma N. 2004. Evaluation of glutathione deficiency in rat livers by microarray analysis. Biochem. Pharmacol. 68: 1465-1475.
18. Kiyosawa N, Uehara T, Gao W, Omura K, Hirode M, Shimizu T, Mizukawa Y, Ono A, Miyagishima T, Nagao T, Urushidani T. 2007. Identification of glutathione depletion-responsive genes using phorone-treated rat liver. J. Toxicol. Sci. 32: 469-486.
19. Lechner MC, Ribeiro VL, Henrique D, Barroso M, Cravino MM. 1990. Modulation of mRNAs P450 and hepatocarcinogenesis promotion. Bull. Cancer 77: 509-514.
20. Liu JJ, Zhang J, Ramanan S, Julian J, Carson DD, Hooi SC. 2004. Heparin/heparan sulfate interacting protein plays a role in apoptosis induced by anticancer drugs. Carcinogenesis 25: 873-879.
21. Liu Y, László C, Liu Y, Liu W, Chen X, Evans SC, Wu S. 2010. Regulation of G(1) arrest and apoptosis in hypoxia by PERK and GCN2-mediated eIF2alpha phosphorylation. Neoplasia 12: 61-68.
22. Mewani RR, Tian S, Li B, Danner MT, Carr TD, Lee S, Rahman A, Kasid UN, Jung M, Dritschilo A, Gokhale PC. 2006. Gene expression profile by inhibiting Raf-1 protein kinase in breast cancer cells. Int. J. Mol. Med. 17: 457-463.
23. Mikula M, Rubel T, Karczmarski J, Goryca K, Dadlez M, Ostrowski J. 2011. Integrating proteomic and transcriptomic high-throughput surveys for search of new biomarkers of colon tumors. Funct. Integr. Genomics. 11: 215-224.
24. Nie AY, McMillian M, Parker JB, Leone A, Bryant S, Yieh L, Bittner A, Nelson J, Carmen A, Wan J, Lord PG. 2006. Predictive toxicogenomics approaches reveal underlying molecular mechanisms of nongenotoxic carcinogenicity. Mol. Carcinogen. 45: 914-933.
25. Nims RW, Sinclair PR, Sinclair JF, Thomas PE, Jones CR, Mellini DW, Syi JL, Lubet RA. 1993. Pharmacodynamics of cytochrome P450 2B induction by phenobarbital, 5-ethyl-5-phenylhydantoin, and 5-ethyl-5-phenyloxazolidinedione in the male rat liver or in cultured rat hepatocytes. Chem. Res. Toxicol. 6: 188-196.
26. Nims RW, McClain RM, Manchand PS, Belica PS, Thomas PE, Mellini DW, Utermahlen WE Jr., Lubet RA. 1994. Comparative pharmacodynamics of hepatic cytochrome P450 2B induction by 5, 5-diphenyl- and 5, 5-diethyl-substituted barbiturates and hydantoins in the male F344/NCr rat. J. Pharmacol. Exp. Ther. 270: 348-355.
27. Omura K, Kiyosawa N, Uehara T, Hirode M, Shimizu T, Miyagishima T, Ono A, Nagao T, Urushidani T. 2007. Gene expression profiling of rat liver treated with serum triglyceride-decreasing compounds. J. Toxicol. Sci. 32: 387-399.
28. Pang J, Liu WP, Liu XP, Li LY, Fang YQ, Sun QP, Liu SJ, Li MT, Su ZL, Gao X. 2010. Profiling protein markers associated with lymph node metastasis in prostate cancer by DIGE-based proteomics analysis. J. Proteome Res. 9: 216-226.
29. Schoonjans K, Staels B, Grimaldi P, Auwerx J. 1993. Acyl-CoA synthetase mRNA expression is controlled by fibric-acid derivatives, feeding and liver proliferation. Eur. J. Biochem. 216: 615-622.
30. Takashima K, Mizukawa Y, Morishita K, Okuyama M, Kasahara T, Toritsuka N, Miyagishima T, Nagao T, Urushidani T. 2006. Effect of the difference in vehicles on gene expression in the rat liver-analysis of the control data in the Toxicogenomics Project Database. Life Sci. 78: 2787-2796.
31. Tasaki M, Shimada K, Kimura H, Tsujikawa K, Konishi N. 2011. ALKBH3, a human AlkB homologue, contributes to cell survival in human non-small-cell lung cancer. Br. J. Cancer 104: 700-706.
32. Uehara T, Hirode M, Ono A, Kiyosawa N, Omura K, Shimizu T, Mizukawa Y, Miyagishima T, Nagao T, Urushidani T. 2008a. A toxicogenomics approach for early assessment of potential non-genotoxic hepatocarcinogenicity of chemicals in rats. Toxicology 250: 15-26.
33. Uehara T, Kiyosawa N, Hirode M, Omura K, Shimizu T, Ono A, Mizukawa Y, Miyagishima M, Nagao T, Urushidani T. 2008b. Gene expression profiling of methapyrilene-induced hepatotoxicity in rat. J. Toxicol. Sci. 33: 37-50.
34. Uehara T, Kiyosawa N, Shimizu T, Omura K, Hirode M, Imazawa T, Mizukawa Y, Ono A, Mizukawa Y, Miyagishima M, Nagao T, Urushidani T. 2008c. Species differences in coumarin-induced hepatotoxicity as an example of how toxicogenomics help assessing risks for human. Human Exp. Toxicol. 27: 23-35.
35. Uehara T, Minowa Y, Morikawa Y, Kondo C, Maruyama T, Kato I, Nakatsu N, Igarashi Y, Ono A, Hayashi H, Mitsumori K, Yamada H, Ohno Y, Urushidani T. 2011. Prediction model of potential hepatocarcinogenicity of rat hepatocarcinogens using a large-scale toxicogenomics database. Toxicol. Appl. Pharmacol. 2011; 255: 297-306.
36. Urushidani T. 2007. Prediction of hepatotoxicity based on the toxicogenomics database. In Hepatotoxicity from Genomics to In Vitro and In Vivo Models, Sahu SC (ed.). Wiley & Sons: New York; 507-529.
37. Yokoyama Y, Kuramitsu Y, Takashima M, Iizuka N, Toda T, Terai S, Sakaida I, Oka M, Nakamura K, Okita K. 2004. Proteomic profiling of proteins decreased in hepatocellular carcinoma from patients infected with hepatitis C virus. Proteomics 4: 2111-2116.